| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation"NCT04204252 | KMDA | Phase 3 | Terminated | 2026-02-19Actual |
| The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.NCT04207736 | ALDX | Phase 3 | Completed | 2021-02-16Actual |
| A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 StudyNCT04215146 | Oncolytics Biotech | Phase 2 | Active not recruiting | 2022-08-01Actual |
| Actuate 1901: 9-ING-41 in MyelofibrosisNCT04218071 | ACTU | Phase 2 | Completed | 2022-10-13Actual |
| Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic CardiomyopathyNCT04219826 | Cytokinetics | Phase 2 | Completed | 2023-02-28Actual |
| Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs PlaceboNCT04221230 | NMRA | Phase 2 | Completed | 2022-04-08Actual |
| Phase 2a Study of ZW25 in Combination With Palbociclib Plus FulvestrantNCT04224272 | Jazz Pharmaceuticals | Phase 2 | Completed | 2023-04-28Actual |
| Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2NCT04229979 | Sellas Life Sciences Group | Phase 3 | Active not recruiting | 2025-12Estimated |
| Study of Cingal® and Triamcinolone Hexacetonide for the Relief of Knee Osteoarthritis PainNCT04231318 | ANIK | Phase 3 | Completed | 2022-05-16Actual |
| D-PLEX 311: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional InfectionNCT04233424 | PYPD | Phase 3 | Completed | 2022-09-02Actual |
| ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile InfectionNCT04247542 | ACXP | Phase 2 | Completed | 2023-10-03Actual |
| Gene Therapy for Fanconi Anemia, Complementation Group ANCT04248439 | RCKT | Phase 2 | Active not recruiting | 2026-05-05Estimated |
| Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination TreatmentNCT04256707 | KPTI | Phase 1, Phase 2 | Completed | 2024-07-31Actual |
| Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCCNCT04260126 | PDSB | Phase 2 | Completed | 2025-05-14Actual |
| A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBCNCT04262804 | Zai Lab (Shanghai) Co., Ltd. | Phase 2 | Unknown | 2021-09-03Actual |
| Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung CancerNCT04262856 | RCUS | Phase 2 | Completed | 2025-07-09Actual |
| Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)NCT04264442 | Fulcrum Therapeutics | Phase 2 | Terminated | 2024-11-07Actual |
| Dexmedetomidine in the Treatment of Agitation Associated With SchizophreniaNCT04268303 | BioXcel Therapeutics Inc | Phase 3 | Completed | 2020-05-06Actual |
| Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)NCT04270682 | MIRM | Phase 3 | Completed | 2023-07-13Actual |
| Dexmedetomidine in the Treatment of Agitation Associated With Bipolar DisorderNCT04276883 | BioXcel Therapeutics Inc | Phase 3 | Completed | 2020-05-21Actual |
| Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett SyndromeNCT04279314 | ACAD | Phase 3 | Completed | 2022-08-19Actual |
| A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)NCT04282980 | Zai Lab (Shanghai) Co., Ltd. | Phase 2 | Completed | 2021-02-26Actual |
| Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque PsoriasisNCT04286607 | ARQT | Phase 3 | Completed | 2024-01-22Actual |
| A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant RecipientsNCT04294472 | VERA | Phase 2 | Completed | 2022-02-10Actual |
| ANAVEX2-73 Study in Pediatric Patients With Rett SyndromeNCT04304482 | AVXL | Phase 2, Phase 3 | Completed | 2023-06-01Actual |
| An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary AngioedemaNCT04307381 | IONS | Phase 2 | Completed | 2025-01-24Actual |
| Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)NCT04308395 | SLGL | Phase 3 | Terminated | 2021-07-14Actual |
| A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal AdenomasNCT04308590 | Corcept Therapeutics | Phase 3 | Completed | 2024-09-19Actual |
| Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)NCT04313153 | Akebia Therapeutics | Phase 3 | Completed | 2021-11-26Actual |
| OLE of Phase 2b/3 Study ANAVEX2-73-AD-004NCT04314934 | AVXL | Phase 2, Phase 3 | Completed | 2024-06-14Actual |
Trial details
- Registry ID
- NCT04204252
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04207736
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04215146
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04218071
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04219826
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04221230
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04224272
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04229979
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04231318
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04233424
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04247542
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04248439
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04256707
- Phase
- Phase 1, Phase 2
Trial details
- Registry ID
- NCT04260126
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04262804
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04262856
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04264442
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04268303
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04270682
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04276883
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04279314
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04282980
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04286607
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04294472
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04304482
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT04307381
- Phase
- Phase 2
Trial details
- Registry ID
- NCT04308395
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04308590
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04313153
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04314934
- Phase
- Phase 2, Phase 3
Primary completion marks the end of data collection for the main study measures, not a results publication date.